FUTURE DR REDDYS Directors Report

Dear members,


The directors are pleased to present the 33rd annual report for the year ended 31 March 2017.


FINANCIAL HIGHLIGHTS


Table 1 gives the financial highlights of the company for FY2017 as compared to the previous financial year, on Ind AS consolidated and standalone basis.


COMPANY AFFAIRS


The company''''s standalone net revenue for the year was '''' 103.11 billion, a decline of 2.88% over the previous year. In US$ terms, this amounted to $ 1.59 billion. Profit before tax (PBT) was '''' 15.45 billion, a decline of 7.88% over the previous year. In US$ terms, this translates into $ 238 million.


Consolidated net revenue for the year was '''' 143.68 billion, a decline of 9.43% over the previous year. In US$ terms, this amounted to $ 2.21 billion. PBT was '''' 15.54 billion, a decline of 45.65% over the previous year. In US$ terms, this translates into $ 240 million.


TABLE ij FINANCIAL HIGHLIGHTS ('''' Million)









































































































































CONSOLIDATED



STANDALONE



FY2017



FY2016



FY2017



FY2016



Total revenue



143,676



158,633



103,110



106,168



Profit before depreciation, amortization and tax



25,803



37,977



22,796



23,261



Depreciation and amortization



10,266



9,389



7,351



6,495



Profit before tax



15,537



28,588



15,445



16,766



Tax expense



2,965



7,511



1,604



3,023



Profit after tax



12,572



21,077



13,841



13,743



Share of profit of equity accounted investees, net of tax



349



229



-



-



Net profit for the year



12,921



21,306



13,841



13,743



Add: surplus at the beginning of the year



82,595



67,074



79,930



72,058



Total available for appropriation



95,516



88,380



93,771



85,801



Appropriations:



Dividend paid during the year



3,312



3,411



3,312



3,411



Tax on dividend paid



674



694



674



694



Credit of dividend distribution tax



(596)



-



(633)



(32)



Transfer to general reserve



1,355



1,679



1,355



1,679



Others



-



-



-



119



Balance carried forward



90,771



82,595



89,063



79,930




Revenue from Global Generics declined by 10% and stood at '''' 115.41 billion, driven largely by North America and Emerging Markets.


Revenue from North America declined by 16% and stood at '''' 63.6 billion. This is primarily on account of increased competition in our key products namely Valganciclovir, Decitabine, Azacitidine etc. coupled with discontinuation of the McNeil business. During the year, the company launched 10 products, the major ones being Omeprazole Sodium Bicarbonate and Nitroglycerin Sublingual tablets. FY2017 also saw 26 ANDA filings in the USA. As of 31 March 2017, cumulatively 101 generic filings are pending for approval with the USFDA (99 ANDAs and two NDAs under 505(b)(2) route). Of these 99 ANDAs, 62 are Para IVs out of which we believe 21 have ''''First to File'''' status.


Revenue from Emerging Markets was '''' 21.1 billion, a decline of 11% on a year-on-year basis. Revenue from India stood at '''' 23.1 billion, registering a year-on-year growth of 9%.


Revenues from PSAI stood at '''' 21.3 billion, a decline of 5% on a year-on-year basis. During the year, 82 DMFs were filed globally of which nine were in the US. The cumulative number of DMF filings as of 31 March 2017 was 754.


DIVIDEND


Your directors are pleased to recommend a dividend of '''' 20/- on every equity share of '''' 5/- (400%) for FY2017. The dividend, if approved at the 33rd annual general meeting (AGM), will be paid to those shareholders whose names appear on the register of members of the company as of the end of day on 18 July 2017.


In terms of regulations 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), the company has revised its dividend distribution policy. This policy was originally adopted on 18 May 2009. The policy is attached as Annexure I to the board''''s report.


TRANSFER TO RESERVES


The company proposes to transfer '''' 1,355 million to the general reserve.


SHARE CAPITAL


The paid-up share capital of your company decreased by '''' 24.33 million to '''' 828.71 million in FY2017 due to the following:


(a) Buyback and extinguishment of 5,077,504 equity shares,


(b) Allotment of 211,564 equity shares, on exercise of stock options by eligible employees of Dr. Reddy''''s, through the ''''Employees Stock Option Scheme, 2002'''' and ''''Dr. Reddy''''s Employees ADR Stock Option Scheme, 2007''''.


FIXED DEPOSITS


The company has not accepted any deposits covered under chapter V of the Companies Act, 2013. Accordingly, no disclosure or reporting is required in respect of details relating to deposits.


CHANGE IN THE NATURE OF BUSINESS, IF ANY


During the year, there was no change in the nature of business of the company or any of its subsidiaries.


MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY


None.


SUBSIDIARIES AND ASSOCIATES


The company had 47 subsidiaries and three joint venture companies as on


31 March 2017. During FY2017,


Imperial Credit Private Limited and Dr. Reddy''''s Laboratories Kazakhstan LLP, have become subsidiary companies and Reddy Cheminor SA in France, was closed and ceased to be a wholly-owned subsidiary. Further, OctoShare BV, OctoPlus Development BV, OctoPlus Technologies BV, OctoPlus Science BV, OctoPlus PolyActive Science BV and Chienna BV ceased to be subsidiaries of the company, upon their merger with Dr. Reddy''''s Research and Development BV (formerly known as OctoPlus BV).


As per section 129(3) of the Companies Act, 2013, where the company has one or more subsidiaries, it shall, in addition to its financial statements, prepare a consolidated financial statement of the company and of all subsidiaries in the same form and manner as that of its own and also attach along with its financial statement, a separate statement containing the salient features of the financial statement of its subsidiaries.


In accordance with the above, the consolidated financial statements of the company and all its subsidiaries and joint ventures, prepared in accordance with Indian Accounting Standards (Ind AS) 110 and 111 as specified in the Companies (Indian Accounting Standards) Rules, 2015, form part of the annual report. Further, a statement containing the salient features of the financial statement of our subsidiaries and joint ventures in the prescribed form AOC-1, is attached as Annexure II to the board''''s report. This statement also provides details of the performance and financial position of each subsidiary.


In accordance with section 136 of the Companies Act, 2013, the audited financial statements and related information of the subsidiaries, where applicable, will be available for inspection during regular business hours at our registered office in Hyderabad, India. These are also available on the company''''s website: www.drreddys.com.


PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS


The company makes investments or extends loans/guarantees to its wholly owned subsidiaries for their business purposes. Details of loans, guarantees and investments covered under section 186 of the Companies Act, 2013, along with the purpose for which such loan or guarantee was proposed to be utilized by the recipient, form part of the notes to the financial statements provided in this annual report.


CORPORATE GOVERNANCE AND ADDITIONAL SHAREHOLDERS'''' INFORMATION


A detailed report on the corporate governance systems and practices of the company is given in a separate chapter of this annual report. Similarly, other information for shareholders is provided in the chapter additional shareholders'''' information. A certificate from the statutory auditors of the company confirming compliance with the conditions of corporate governance is attached to the corporate governance report.


MANAGEMENT DISCUSSION AND ANALYSIS


A detailed report on the management discussion and analysis in terms of the provisions of regulation 34 of the Listing Regulations, is provided as a separate chapter in the annual report.


BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL


The term of Mr. Ravi Bhoothalingam as an independent director of the company ended on 27 July 2016. The board places on record its appreciation for the services rendered by Mr. Bhoothalingam during his tenure as a member of the board and its committees.


The board of directors at its meeting held on 12 May 2017, had re-appointed Mr. K Satish Reddy as whole-time director designated as chairman of the company (or such other designation as the board may deem fit), for a further period of five years with effect from 1 October 2017 (including terms and conditions of the appointment), subject to approval of the shareholders at the forthcoming 33rd AGM scheduled on 28 July 2017.


In accordance with section 149(7) of the Companies Act, 2013, each independent director has confirmed to the company that he or she meets the criteria of independence laid down in section 149(6) of the Companies Act, 2013 and regulation 16(1)(b) of the Listing Regulations.


Mr. G V Prasad, retires by rotation at the forthcoming 33rd AGM and being eligible, seeks re-appointment.


Brief profiles of Mr. K Satish Reddy and Mr. G V Prasad are given in the corporate governance section of the annual report and notice convening the 33rd AGM for reference of the shareholders.


BOARD EVALUATION


As per provisions of the Companies Act, 2013 and regulation 17(10) of the Listing Regulations, an evaluation of the performance of the board and members was undertaken. For details, please see the chapter on corporate governance in this annual report.


APPOINTMENT OF DIRECTORS AND REMUNERATION POLICY


The assessment and appointment of members to the board is based on a combination of criteria that includes ethics, personal and professional stature, domain expertise, gender diversity and specific qualification required for the position. A potential board member is also assessed on the basis of the independence criteria defined in section 149(6) of the Companies Act, 2013 and regulation 16(1)(b) of the Listing Regulations.


In accordance with section 178(3) of the Companies Act, 2013, regulation 9(4) of the Listing Regulations and on recommendations of the nomination, governance and compensation committee, the board adopted a remuneration policy for directors, key managerial personnel (KMPs) and senior management. The policy is attached to the corporate governance report.


NUMBER OF BOARD MEETINGS


The board of directors met four times during the year. In addition, an annual board retreat was held to discuss strategic matters. Details of board meetings are given in the corporate governance report.


AUDIT COMMITTEE


The audit committee of the board of directors consists entirely of independent directors. Presently, the committee comprises Mr. Sridar Iyengar (chairman), Ms. Kalpana Morparia, Dr. Omkar Goswami and Mr. Bharat N Doshi. Further details can be seen in the corporate governance report. The board has accepted all recommendations made by the audit committee during the year.


BUSINESS RISK MANAGEMENT


The company has a risk management committee of the board, consisting entirely of independent directors.


Details of the committee and its terms of reference are set out in the corporate governance report.


The audit and risk management committees review key risk elements of the company''''s business, finance, operations and compliance and respective mitigation strategies. The risk management committee reviews key strategic, business, compliance and operational risks, while issues around ethics and fraud, internal control over financial reporting (ICOFR), as well as process risks and their mitigation are reviewed by the audit committee.


The company''''s finance, investment and risk management council (FIRM council) is a management level committee which operates under a charter and focuses on risks associated with the company''''s business and investments. The FIRM council periodically reviews matters pertaining to ethics and fraud, compliance and internal audit. Additionally, the enterprise-wide risk management (ERM) function helps the management and the board to periodically prioritize, review and measure business risks against a pre-determined risk appetite and their suitable response, depending on whether such risks are internal, strategic or external.


During FY2017, focus areas of risk management included progress on strategy execution, quality and regulatory, geo-political, compliance and patent infringement risk exposures, safety and health.


ADEQUACY OF INTERNAL FINANCIAL CONTROL SYSTEMS


The company has in place adequate internal financial controls with reference to financial statements. These controls ensure the accuracy and completeness of the accounting records and preparation of reliable financial statements.


DIRECTORS'''' RESPONSIBILITY STATEMENT


In terms of section 134(5) of the Companies Act, 2013, (''''the Act''''), your directors state that:


1. applicable accounting standards have been followed in the preparation of the annual accounts;


2. accounting policies have been selected and applied consistently. Judgments and estimates made are reasonable and prudent, so as to give a true and fair view of the state of affairs of the company at the end of the FY2017 and of the profit of the company for that period;


3. proper and sufficient care has been taken to maintain adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;


4. annual accounts have been prepared on a going concern basis;


5. adequate internal financial controls for the company to follow have been laid down and these are operating effectively; and


6. proper and adequate systems have been devised to ensure compliance with the provisions of all applicable laws and these systems are operating effectively.


RELATED PARTY TRANSACTIONS


In accordance with section 134(3)(h) of the Companies Act, 2013 and rule 8(2) of the Companies (Accounts) Rules, 2014, the particulars of contract or arrangement entered into by the company with related parties referred to in section 188(1) in form AOC-2 is attached as Annexure III. All such contracts or arrangements are in the interest of the company. Details of related party disclosures form part of the notes to the financial statements provided in this annual report.


VIGIL MECHANISM/WHISTLE BLOWER POLICY


The company has an ombudsperson policy (whistle blower/vigil mechanism) to report concerns. The vigil mechanism consists of a hotline - a dedicated email-ID and a phone number. The ombudsperson policy safeguards from victimization of those who use this mechanism. An audit committee member is the chief ombudsperson. The policy also provides access to the chairperson of the audit committee under certain circumstances. Details of the policy are also available on the company''''s website: www.drreddys.com/investors/ governance/ombudsperson-policy


STATUTORY AUDITORS


M/s. S R Batliboi & Associates LLP, chartered accountants (firm registration no. 101049W/E300004) were appointed as statutory auditors of the company at the 32 nd AGM held on 27 July 2016, for a period of 5 years commencing from the conclusion of 32nd AGM till the conclusion of the 37th AGM, subject to ratification by shareholders every year, as may be applicable. The firm has consented and confirmed that the appointment is within the limits specified under section 141(3)(g) of the Companies Act, 2013. The statutory auditors have also confirmed that they are not disqualified to be appointed as such in terms of the proviso to section 139(1), section 141(2) and section 141(3) of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014.


The audit committee and the board of directors recommend to the shareholders the ratification of appointment of M/s. S R Batliboi & Associates LLP, chartered accountants, as statutory auditors of the company from the conclusion of the 33rd AGM till the conclusion of 34th AGM.


SECRETARIAL AUDITOR


Pursuant to section 204 of the Companies Act, 2013 and the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014,


Dr. K R Chandratre, practicing company secretary (membership no. FCS 1370 and certificate of practice no. 5144) was appointed to conduct the secretarial audit of the company for FY2017. The secretarial audit report for FY2017 is attached as Annexure IV.


Based on the consent received from Dr. K R Chandratre, and on the recommendations of the audit committee, the board has appointed him as the secretarial auditor of the company for FY2018.


COST AUDITORS


Pursuant to section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 and the Companies (Cost Records and Audit) Amendment Rules, 2014, the company maintains the cost audit records in respect of its pharmaceutical business. On recommendation of the audit committee, your board has appointed M/s. Sagar & Associates, cost accountants (firm registration no. 000118) as cost auditors of the company for the FY2018 at a remuneration of '''' 7 lakhs plus reimbursement out of pocket expenses at actuals and applicable taxes. The provisions also require that the remuneration of the cost auditors be ratified by the shareholders. As a matter of record, relevant cost audit reports for FY2016 were filed with the Central Government on 24 August 2016, within the stipulated timeline. The cost audit reports for FY2017 will be also filed within the timeline.


BOARD''''S RESPONSE ON AUDITOR''''S QUALIFICATION, RESERVATION OR ADVERSE REMARK OR DISCLAIMER MADE


There are no qualifications, reservations or adverse remarks made by the statutory auditors in their report or by the practicing company secretary in the secretarial audit report. During the year, there were no instances of frauds reported by auditors under section 143(12) of the Companies Act, 2013.


SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE COURTS/REGULATORS


None.


INFORMATION REQUIRED UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013


The company has an apex complaints committee and an internal complaints committee which operate under a defined redressal system for complaints pertaining to sexual harassment of women at workplace. Details are available in the principle 3 under section 7 of the business responsibility report forming a part of this annual report.


CORPORATE SOCIAL RESPONSIBILITY (CSR) INITIATIVES


As per section 135 of the Companies Act, 2013, the company has a board level CSR committee consisting of Mr. Bharat N Doshi (chairman), Mr. G V Prasad and Mr. K Satish Reddy. The company''''s CSR policy provides a constructive framework to review and organize our social outreach programs in health, livelihood and education. During the year, the committee monitored implementation and adherence to the CSR policy. Details about the CSR policy and initiatives taken by the company during the year are available on the company''''s website: www.drreddys.com. The report on CSR activities is attached as Annexure V.


BUSINESS RESPONSIBILITY REPORT


A detailed business responsibility report in term of the provisions of regulation 34 of the Listing Regulations, is available as a separate section in this annual report.


TRANSFER OF UNPAID AND UNCLAIMED AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)


Pursuant to the provisions of the Companies Act, 2013, read with IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, declared dividends which remained unpaid or unclaimed for a period of seven years have been transferred by the company to the IEPF, which has been established by the central government.


The above referred rules now mandate transfer of dividends lying unpaid and unclaimed for a period of seven years as well as the underlying equity shares to IEPF. The company has issued individual notices to the shareholders whose equity shares are liable to be transferred to IEPF, advising them to claim their dividend on or before 31 May 2017.


EMPLOYEES STOCK OPTION SCHEMES


During the year, there has been no material change in the ''''Dr. Reddy''''s Employees Stock Option Scheme, 2002'''' and the ''''Dr. Reddy''''s Employees ADR Stock Option Scheme, 2007'''' (both collectively referred as ''''the schemes''''). The schemes are in compliance with the SEBI (Share Based Employee Benefits) Regulations,


2014. The details are available on the company''''s website: www.drreddys.com/ pdf/ESOP_details.pdf.


The details also form part of note 2.28 of the notes to accounts of the standalone financial statements.


PARTICULARS OF EMPLOYEES


Disclosures pertaining to remuneration and other details as required under section 197(12) of the Companies Act, 2013, read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are attached as Annexure VI.


In terms of section 197(12) of the Companies Act, 2013, read with rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement showing the names and other particulars of the employees drawing remuneration in excess of limits set out in said rules forms part of the annual report.


Considering the first proviso to section 136(1) of the Companies Act, 2013, the annual report, excluding the aforesaid information, is being sent to the shareholders of the company and others entitled thereto. The said information is available for inspection at the registered office of the company during business hours on working days up to the date of the forthcoming 33rd AGM. Any shareholder interested in obtaining a copy thereof may write to the company secretary in this regard.


CONSERVATION OF ENERGY, RESEARCH & DEVELOPMENT, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO


The particulars as prescribed under section 134(3)(m) of the Companies Act, 2013, read with rule 8(3) of the Companies (Accounts) Rules, 2014 are attached as Annexure VII.


EXTRACT OF THE ANNUAL RETURN


Details forming part of the extract of the annual return in form MGT-9 are attached as Annexure VIII.


ACKNOWLEDGEMENT


Your directors place on record their sincere appreciation for the significant contribution made by our employees through their dedication, hard work and commitment, as also for the trust reposed in us by the medical fraternity and patients. We also acknowledge the support extended to us by the analysts, bankers, government agencies, media, customers, suppliers, shareholders and investors at large. We look forward to your continued support in our endeavor to accelerate access to innovative and affordable medicines because Good Health Can''''t Wait.


for and on behalf of the


board of directors


K Satish Reddy


Chairman


Place: Hyderabad Date: 12 May 2017

CIN: U67190WB2003PTC096617. Trading in Commodities is done through our Group Company Dynamic Commodities Pvt. Ltd. The company is also engaged in Proprietory Trading apart from Client Business.
“2019 © COPYRIGHT DYNAMIC EQUITIES PVT. LTD.”

Disclaimer: There is no guarantee of profits or no exceptions from losses. The investment advice provided are solely the personal views of the research team. You are advised to rely on your own judgment while making investment / Trading decisions. Past performance is not an indicator of future returns. Investment is subject to market risks. You should read and understand the Risk Disclosure Documents before trading/Investing.

Disclosure: We, Dynamic Equities Private Limited are also engaged in Proprietory Trading apart from Client Business. In case of any complaints/grievances, clients may write to us at compliance@dynamiclevels.com

  • Download our Mobile App
  • Available on Google Play
  • Available on App Store
  • RSS